---
title: "AstraZeneca Slides After Wainua Misses Cardiovascular Goal in Late-Stage Trial"
publisher: "Stockmark.IT"
author: "Stockmark.IT Website"
published: "2026-07-12T08:40:39+00:00"
modified: "2026-07-12T08:40:39+00:00"
date: 2026-07-12
canonical: "https://stockmark.it/astrazeneca-slides-after-wainua-misses-cardiovascular-goal-in-late-stage-trial/"
category: "Pharmaceutical"
categories: ["Pharmaceutical"]
image: "https://i0.wp.com/stockmark.it/wp-content/uploads/stencil.default-2025-02-04T060534.489.jpg?fit=1200%2C800&quality=89&ssl=1"
format: "news"
language: "en-GB"
---

# AstraZeneca Slides After Wainua Misses Cardiovascular Goal in Late-Stage Trial

**Published:** July 12, 2026
**Author:** Stockmark.IT Website
**Categories:** Pharmaceutical
**Featured image:** ![Glass building with AstraZeneca written on top in large white letters. The companys logo, a stylized double helix, appears in yellow next to the name. The buildings modern architecture features numerous reflective windows against a pale sky.](https://i0.wp.com/stockmark.it/wp-content/uploads/stencil.default-2025-02-04T060534.489.jpg?fit=1200%2C800&quality=89&ssl=1)

---

> AstraZeneca shares dropped after Wainua failed to reduce cardiovascular deaths and recurrent heart events in a late-stage trial, dragging on the FTSE 100.

**AstraZeneca shares fell sharply **after **Wainua failed to meet the primary cardiovascular endpoint in a late-stage study,** weighing heavily on the FTSE 100 and the wider UK pharmaceutical sector.

AstraZeneca PLC (LSE: AZN), together with US partner Ionis Pharmaceuticals, reported that Wainua did not achieve the study’s main objective of reducing cardiovascular deaths and recurrent cardiovascular events. Reuters reported that AstraZeneca shares fell 6.2% on 9 July, while the UK pharmaceutical index declined 4.3%.

The setback contributed to the FTSE 100 closing 0.2% lower at 10,472.5, despite gains in mining and banking shares.

Late-stage trial failures can materially alter revenue expectations, development timelines and capital-allocation decisions. AstraZeneca’s large index weighting also means company-specific clinical news can affect the direction of the wider UK market.

## Company details

- **Company:** AstraZeneca PLC

- **Ticker:** LSE: AZN

- **Partner:** Ionis Pharmaceuticals, NASDAQ: IONS

- **Drug:** Wainua

- **Sector:** Pharmaceuticals

- **Release time:** Reuters market report published 9 July 2026, 11:03 UTC

**Source:** Reuters, based on company trial results and London market data.

---

**Original URL:** https://stockmark.it/astrazeneca-slides-after-wainua-misses-cardiovascular-goal-in-late-stage-trial/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*